Medtronic VP and GM Sandra Lesenfants Joins Osprey Board

Posted: 2017-06-20 in Press Releases

Download PDF

Medtronic VP and GM Sandra Lesenfants Joins Osprey Board


June 20, 2017 – Melbourne, Australia and Minnesota, United States – Osprey Medical (ASX: OSP) today announced the appointment of Sandra Lesenfants to the Osprey Board as a Non-Executive Director.

Mrs. Lesenfants also currently serves as the Vice President & General Manager of endoVenous business in the Medtronic Cardiac & Vascular Group. In her role, she is responsible for leading the development and global marketing of meaningful innovations and solutions to address chronic venous insufficiency, deep venous disease, and embolization.

Notably, Sandra led several key integrations including the acquisition of Sapheon and its VenaSeal closure system, the integration of endoVenous business from Covidien’s Vascular Therapy business into Medtronic, and the integration of the embolization sales team from Medtronic’s Neurovascular division into endoVenous.

Mrs. Lesenfants, has commercial strategy experience and global business management skills from the vascular businesses at Medtronic, Covidien, EV3, and Siemens Healthcare.

Commenting on her appointment to the Board of Directors, Chairman John Erb said: “Mrs. Lesenfants has deep and relevant experience to provide invaluable guidance and input to the Osprey Board at a critical time as we expand our market launch of our DyeVert Plus System in the U.S. and work towards launch in Europe. We welcome her to the Board of Osprey Medical.”

Mrs. Lesenfants is on the Board of Directors of the American Venous Forum Foundation. She has a biomedical computer engineering degree from the University of Technology of Compiegne Engineering Institute in France.


Contact details:






Amanda Loh

Rebecca Wilson

Doug Schoenberg

Buchan Consulting

Buchan Consulting

VP of Marketing

T: (613) 8866 1210

M: (61) 417 382 391

T: (952) 955 8230

About Osprey



Osprey Medical’s vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast Induced Acute Kidney Injury (AKI).  The Company’s core technologies originated from research conducted by Dr David Kaye at Melbourne’s Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company’s DyeVert™ Plus System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical’s Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical’s advisory board comprises world-recognised experts in heart and kidney diseases.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward- looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.